Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson

By Joe Tenebruso - Oct 30, 2017 at 6:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Which of these healthcare leaders is the best choice for your portfolio?

With multiple catalysts likely to fuel its growth, the healthcare sector is fertile ground from which investors can reap sizable profits -- if you know where to look.

To help you in this regard, we're pitting two outstanding healthcare businesses -- Intuitive Surgical (ISRG 2.69%) and Johnson & Johnson (JNJ 1.13%) -- against each other to see which is the best buy today. Let's see which of these stocks is the best place for your investment dollars.

A businessperson sitting in front of a scale that is weighing two sets of coins.

Image source: Getty Images.


Intuitive Surgical dominates the robotic surgery market. Its da Vinci surgical system has faced little competition since its introduction in 1999. And while new competitors are beginning to enter this valuable arena, Intuitive holds a commanding lead built upon its massive installed base of more than 4,000 da Vinci machines currently in use around the world. Surgeons have performed over 4 million procedures to date on da Vinci systems, logging countless hours on them in the process. This helps to strengthen Intuitive's economic moat by increasing its customers' switching costs. The large amount of time and capital doctors and hospitals have already spent to become proficient with these robotic systems makes it difficult for them to switch to a competing product.

Johnson & Johnson's competitive advantage resides in its massive scale, diverse revenue streams, and leading positions in multiple important markets. J&J is a global leader in pharmaceuticals, medical devices, consumer healthcare, and biotechnology, among other areas. Moreover, it reinvests a substantial portion of its massive cash flow every year into research and development, so as to constantly strengthen and expand its leadership position in these industries. It's a virtuous cycle that has benefited shareholders for decades, and that should continue to do so for decades to come.

Both of these businesses possess powerful competitive advantages. But while formidable rivals could pose a potential threat to Intuitive Surgical, it's more difficult to imagine a situation where Johnson & Johnson is unseated from its throne atop the healthcare sector. Thus, I'd argue that J&J has the wider moat.

Advantage: Johnson & Johnson

Financial fortitude

Let's now take a look at some key metrics to see how Intuitive Surgical and Johnson & Johnson stack up in regards to financial strength.


Intuitive Surgical

Johnson & Johnson


$3 billion

$72.5 billion


$1.1 billion

$24.8 billion

Net income

$0.9 billion

$16.3 billion

Operating cash flow

$1.1 billion

$20.7 billion

Free cash flow

$0.9 billion

$17.6 billion

Cash & investments

$3.8 billion

$12.9 billion



$34.6 billion


Intuitive Surgical has a pristine balance sheet with more than $3.8 billion in cash and investments and zero debt. It's also a highly profitable business, with a net profit margin of approximately 30%, which in turn helps fuel its impressive free cash flow generation.

That said, Johnson & Johnson is a financial titan. Even after adjusting for its sizable dividend payout, J&J generates nearly 10 times as much free cash flow as Intuitive does on an annual basis. This -- combined with its diverse revenue streams and bountiful cash reserves -- has earned Johnson & Johnson a triple-A rating from the major credit rating agencies, making it one of only two U.S. companies that can claim that distinction (Microsoft is the other). As such, Johnson & Johnson has the edge in terms of financial fortitude.

Advantage: Johnson & Johnson


Over the past decade, Intuitive's revenue and earnings growth have far exceeded that of Johnson & Johnson.

ISRG Revenue (TTM) Chart

ISRG Revenue (TTM) data by YCharts

Yet over the next five years, Wall Street expects these companies to grow their EPS at surprisingly similar rates: 10.23% for Intuitive and 6.97% for J&J. So Intuitive still comes out ahead, but it's much closer than I expected.

Advantage: Intuitive Surgical


No better-buy discussion should take place without a look at valuation. Let's check out some key value metrics for Intuitive and J&J, including price-to-sales, price-to-earnings, and price-to-free-cash-flow ratios.


Intuitive Surgical

Johnson & Johnson




Trailing P/E



Forward P/E







On all four metrics, Johnson & Johnson's shares are far less expensive than Intuitive Surgical's. Even if we factor in Intuitive's higher expected earnings growth rate over the next five years, it's price-to-earnings-to-growth ratio of 4.17 is still well above J&J's PEG of 2.79. All of these metrics are therefore suggesting the same thing: J&J's stock is currently the better bargain.

Advantage: Johnson & Johnson

The better buy is...

With its wide competitive moat, fortress-like financial position, and more attractively priced stock, Johnson & Johnson is the better buy today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$179.52 (1.13%) $2.01
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$206.10 (2.69%) $5.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.